PMV Pharmaceuticals Inc. (PMVP) News
Filter PMVP News Items
PMVP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PMVP News From Around the Web
Below are the latest news stories about PMV PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PMVP as an investment opportunity.
Discover 3 US Penny Stocks With Market Caps Over $40MAs the U.S. stock market reaches new heights with record closings for the S&P 500 and Nasdaq, investors are exploring diverse opportunities beyond large-cap tech stocks. Penny stocks, while often associated with smaller or newer companies, remain a relevant area for those seeking unique investment possibilities. Despite their vintage-sounding name, these stocks can offer surprising value when backed by strong financials, providing potential for significant returns and stability. |
PMV Pharmaceuticals Reports Third Quarter 2024 Financial ResultsEnrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis expected by mid-2025PMV Pharmaceuticals is collaborating with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center to support an investigator-initiated Phase 1b study evaluating rezatapopt monotherapy and in combinatio |
US Penny Stocks To Consider In October 2024Major U.S. stock indexes have seen a downturn recently, with the Dow Jones, S&P 500, and Nasdaq Composite all experiencing declines amid rising Treasury yields and mixed earnings reports. Despite these fluctuations, there remains potential in the market for those willing to explore beyond established giants. Penny stocks—often representing smaller or newer companies—continue to offer intriguing opportunities for growth at attractive price points when backed by strong fundamentals and solid... |
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical TrialEnrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis expected by mid-2025 Dose-limiting toxicities observed in rezatapopt and Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) combination arm of Phase 1b PYNNACLE trial; rezatapopt 500 mg once-daily in combination with pe |
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth PlansThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical TrialEnrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 60% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis from Phase 2 monotherapy expected by mid-2025 Eligibility criteria in ongoing Phase 1b rezatapopt and pembrolizumab combination arm of PYNNACLE trial adjusted to align with Phase 2 TP53 Y220C and KRAS wild-type patient population Cash |
Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom FisherPMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in JunePRINCETON, N.J., May 30, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences in June. Management will also participate in one-on-one investor meetings. Jefferies |
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorBOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation. Across all human cancers, TP5 |
Here's Why You Should Buy Acrivon Therapeutics (ACRV) StockHere, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move. |